Menu
Sign In Pricing Add Podcast

BackTable Urology

Ep. 193 Bladder Cancer Innovations: ESMO 2024 Highlights with Dr. Andrea Apolo

1247.284 - 1258.232 Dr. Andrea Apolo

And the results just show that adjuvant pembrolizumab is effective in this setting and should be considered an option for patients that have high-risk muscle invasive disease.

0
💬 0

Comments

There are no comments yet.

Log in to comment.